Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Number of JP Drugs to Increase by 84
May 21, 2007
- Teijin: Pharm. Sales Up 7.1% to \113.1 Bil.
May 21, 2007
- Nippon Shinyaku Establishes Technology to Manufacture Long RNA Oligomers
May 21, 2007
- Kaken: Main Products Drive Overall Business
May 21, 2007
- Korosho to Select 10 Chukaku Hospitals, 30 Kyoten Hospitals for Clinical Trials
May 21, 2007
- Torii: Both Sales, Profits Down Due to Slump of Main Products
May 21, 2007
- R&D NEWS IN BRIEF
May 21, 2007
- Olympus: Sales Exceed \1 Tri. with 57.9% Increase in Operating Profits
May 21, 2007
- JT: Sales Down 7.7%, Operating Loss of \11.2 Bil.
May 21, 2007
- HuBit Genomix Begins New Gene Genome Analysis Service Jointly with deCODE
May 21, 2007
- Asahi Kasei Pharma: License Fee on Fasudil Props Up Sales
May 21, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 21, 2007
- Nissan Chemical, Taisho License NM-702 to Milford
May 21, 2007
- On-Line Medical Bill Processing Starting
May 21, 2007
- GSK Recommences Supply of Relenza
May 21, 2007
- JSC to Start Antibacterial Chemotherapy Specialist Certification System
May 21, 2007
- Quintiles Receives Increasing Number of Orders on ECG Analysis Services
May 21, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2007
- Korosho Continues Hearings to Increase Price Agreement Rates
May 21, 2007
- 5-Year Strategy to Develop Innovative Drugs, Med. Devices Proposed
May 14, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…